APDN — Applied DNA Sciences Income Statement
0.000.00%
Last trade - 00:00- $2.43m
- -$4.63m
- $3.43m
- 10
- 72
- 11
- 21
Annual income statement for Applied DNA Sciences, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.93 | 9.03 | 18.2 | 13.4 | 3.43 |
| Cost of Revenue | |||||
| Gross Profit | 1.21 | 4.93 | 5.05 | 5.53 | 1.02 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 14.5 | 23.1 | 32.1 | 24.3 | 17.5 |
| Operating Profit | -12.5 | -14 | -14 | -11 | -14 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -13 | -14.3 | -8.27 | -10 | -7.09 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -13 | -14.3 | -8.27 | -10 | -7.09 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -13 | -14.3 | -8.27 | -9.95 | -6.99 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -13 | -14.3 | -8.38 | -9.95 | -7.23 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -49,869 | -27,171 | -14,013 | -11,411 | -1,366 |